摘要
目的观察培美曲塞与多西他赛联合顺铂治疗晚期肺腺癌的临床效果。方法研究对象取自于我院2013年10月~2014年10月收治的66例晚期肺腺癌患者,按随机数字表法分为对照组（33例）与观察组（33例）。对照组采用多西他赛联合顺铂治疗;观察组采用培美曲塞联合顺铂治疗。记录两组患者治疗期间不良反应发生情况,随访8月,观察两组治疗效果。结果对照组与观察组治疗总有效率分别为45.5%和51.5%,两组比较差异无统计学意义（P〉0.05）;较对照组72.7%,观察组不良反应发生率48.5%低,两组比较差异有统计学意义（P〈0.05）。结论培美曲塞与多西他赛联合顺铂治疗晚期肺腺癌均能取得一定效果,前者治疗不良反应少,更具优势。
Objective To observe the efficacy of pemetrexed and docetaxel combined cisplatin in the treatment of advanced lung adenocarcinoma. Methods Research object derived from October 2013 to October 2014,66 cases of patients with advanced lung adenocarcinoma,according to random number table method,was divided into control group（33 cases）and observation group（33 cases）,control group adopted docetaxel with cisplatin therapy,observation group was treated with pemetrexed combined cisplatin,recorded of two groups of patients during treatment and the adverse reaction followed up for 8 months,two groups of treatment effect were observed. Results The control group and observation group total effective rate were 45.5% and 51.5% respectively,were similar between the two groups had no statistical significance（P〉0.05）. Incidence of adverse reactions in observation group（72.7%）were lower than the control group（48.5%）,comparing the two groups was statistically significant difference（P〈0.05）. Conclusion Pemetrexed and docetaxel combined cisplatin treatment of advanced lung adenocarcinoma must effect can be obtained,less adverse reaction,the former treatment is much more advantages and is suitable for clinical promotion.
出处
《中国卫生标准管理》
2015年第28期126-127,共2页
China Health Standard Management
关键词
培美曲塞
顺铂
多西他赛
晚期肺腺癌
Pemetrexed
Cisplatin
docetaxel
Advanced lung adenocarcinoma
